[Go]
PubMed | Entrez | Structure | PubChem | Help
PubChem  » Substance Summary
 


alizarin - Substance Summary (SID 586494)

RN given refers to cpd with specified hydroxy locants


Drug and Chemical Information: (Total:1)         

Safety and Toxicology

CCRIS - Carcinogenicity, tumor promotion, tumor inhibition, and mutagenicity tests

EINECS - European Inventory of Existing Commercial Chemical Substances

GENETOX - Genetic toxicology information

TOXLINE - Citations to the toxicological literature


Literature

Literature Keyword Mining Tool



Data Source:   

Depositor: NMRShiftDB
External ID: 2336

Depositor-Supplied Synonyms: (Total: 8)
Sort:
Alizarin
Hystazarin
1,2-Dihydroxy-anthraquinone
1,2-Dihydroxy-9,10-anthracenedione
9,10-Anthracenedione, 1,2-dihydroxy-
1,2-Dihydroxyanthra-9,10-quinone
72-48-0
InChI=1/C14H8O4/c15-10-6-5-9-11(14(10)18)13(17)8-4-2-1-3-7(8)12(9)16/h1-6,15,18


Properties Computed from Structure:
Molecular Weight240.21092 [g/mol]
Molecular FormulaC14H8O4
XLogP33.2
H-Bond Donor2
H-Bond Acceptor4
Rotatable Bond Count0
Tautomer Count16
Exact Mass240.042259
MonoIsotopic Mass240.042259
Topological Polar Surface Area74.6
Heavy Atom Count18
Formal Charge0
Complexity378
Isotope Atom Count0
Defined Atom StereoCenter Count0
Undefined Atom StereoCenter Count0
Defined Bond StereoCenter Count0
Undefined Bond StereoCenter Count0
Covalently-Bonded Unit Count1


Descriptors Computed from Structure:
IUPAC Name: 1,2-dihydroxyanthracene-9,10-dione
Canonical SMILES: C1=CC=C2C(=C1)C(=O)C3=C(C2=O)C(=C(C=C3)O)O
InChI: InChI=1S/C14H8O4/c15-10-6-5-9-11(14(10)18)13(17)8-4-2-1-3-7(8)12(9)16/
h1-6,15,18H

InChIKey: RGCKGOZRHPZPFP-UHFFFAOYSA-N


Substance Information:
SID 586494   
Deposit Date: 2006-01-25
Modify Date: 2007-02-15

CID 6293   
Create Date: 2004-09-16

Related Substances:
Same: 61 Links

Similar Substances: 740 Links

     
Compound Displayed

2D

3D

Compound ID6293
Molecular Weight240.21092 [g/mol]
Molecular FormulaC14H8O4
XLogP33.2
H-Bond Donor2
H-Bond Acceptor4


 Write to Helpdesk | Disclaimer | Privacy statement | Accessibility